Pavel Hamet

Direktor/Vorstandsmitglied bei

Bellus Health (Innodia), Inc.

Health Technology

Consumer Services

Finance

Profil

Pavel Hamet was the founder of Prognomix, Inc. (2005) with the title of President, Co-Chief Executive Officer & Director.
Current jobs include Director at Bellus Health (Innodia), Inc., Director at Canadian Institutes of Health Research, Director at Medpharmgene, Inc., Director at Société Francophone Du Diabete since 2010, and Professor at the University of Montréal.
Former jobs include Chairman at Canada Foundation for Innovation, Director at AGC Biologics SpA, Director at BioCapital Investment Advisors, Inc. from 2003 to 2005, Director at Société de développement Angus, and President at Canadian Hypertension Society.
Education includes a doctorate from McGill University (1972) and a doctorate from the University of Charles (1967).

Aktive Positionen von Pavel Hamet

Unternehmen	Position	Beginn
Bellus Health (Innodia), Inc. Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products	Direktor/Vorstandsmitglied	-
Canadian Institutes of Health Research Canadian Institutes of Health Research Miscellaneous Commercial ServicesCommercial Services Operates as funding agency for health research activities	Direktor/Vorstandsmitglied	02.06.2010
University of Montréal University of Montréal Other Consumer ServicesConsumer Services Functions as a College/University	Corporate Officer/Principal	-
Société Francophone Du Diabete	Direktor/Vorstandsmitglied	01.01.2010
Medpharmgene, Inc. Medpharmgene, Inc. Miscellaneous Commercial ServicesCommercial Services Provides commercial physical research services	Direktor/Vorstandsmitglied	-

Alle aktiven Positionen von Pavel Hamet

Ehemalige bekannte Positionen von Pavel Hamet

Unternehmen	Position	Ende
Prognomix, Inc. Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Develops market molecular diagnostic kits for testing of diabetes complications	Gründer	13.01.2015
BioCapital Investment Advisors, Inc. BioCapital Investment Advisors, Inc. Investment ManagersFinance The fundamental investment objective of BioCapital is to provide investors superior capital appreciation by investing in equity securities of public companies with high growth potential in biotechnology industries. They seek to achieve this fundamental objective by investing in a diversified portfolio of public companies primarily in the following sectors of the biotechnology industry: therapeutics in the fields of cancer, cardiology, infectious diseases, immune system and central nervous system. The firm also invests in companies developing platform technologies in the fields on genomics and proteomics, drug delivery, theranostics, nanotechnology and monoclonal antibody.	Direktor/Vorstandsmitglied	31.12.2005
Société de développement Angus Société de développement Angus Real Estate DevelopmentFinance Engages in development and project management of urban revitalization projects	Direktor/Vorstandsmitglied	-
Canadian Hypertension Society	Präsident	-
░░░░░░ ░░░░░░░░░░ ░░░ ░░░░░░░░░░	░░░░░░░░░░░░	-

Sehen Sie sich die Erfahrung von Pavel Hamet im Detail an

Ausbildung von Pavel Hamet

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Pavel Hamet im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	13
AGC Biologics SpA AGC Biologics SpA Pharmaceuticals: MajorHealth Technology Provides pharmaceutical development and manufacturing services for protein-based biologics, cells & gene therapies and messenger RNA	Health Technology
BioCapital Investment Advisors, Inc. BioCapital Investment Advisors, Inc. Investment ManagersFinance The fundamental investment objective of BioCapital is to provide investors superior capital appreciation by investing in equity securities of public companies with high growth potential in biotechnology industries. They seek to achieve this fundamental objective by investing in a diversified portfolio of public companies primarily in the following sectors of the biotechnology industry: therapeutics in the fields of cancer, cardiology, infectious diseases, immune system and central nervous system. The firm also invests in companies developing platform technologies in the fields on genomics and proteomics, drug delivery, theranostics, nanotechnology and monoclonal antibody.	Finance
McGill University McGill University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of Montréal University of Montréal Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Bellus Health (Innodia), Inc. Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products	Health Technology
University of Charles University of Charles Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Prognomix, Inc. Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Develops market molecular diagnostic kits for testing of diabetes complications	Health Technology
Canada Foundation For Innovation Canada Foundation For Innovation Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment	Miscellaneous
Canadian Institutes of Health Research Canadian Institutes of Health Research Miscellaneous Commercial ServicesCommercial Services Operates as funding agency for health research activities	Commercial Services
Canadian Hypertension Society
Medpharmgene, Inc. Medpharmgene, Inc. Miscellaneous Commercial ServicesCommercial Services Provides commercial physical research services	Commercial Services
Société de développement Angus Société de développement Angus Real Estate DevelopmentFinance Engages in development and project management of urban revitalization projects	Finance
Société Francophone Du Diabete